Samyang Holdings Biopharm Group (Div.) announced that it signed a joint research and development agreement with Azos Bio, a company specializing in the development of new drugs based on AI platforms, at the Samyang Discovery Center in Pangyo for the development of cationic lipids for nucleic acid delivery systems.
Nucleic acids are essential substances that contain the genetic information necessary to sustain life, and are used as key drugs such as vaccines and anticancer drugs. Nucleic acids are easily decomposed in the body, so a delivery vehicle that can stably protect the drug and deliver it to the desired target organ is essential.
In March of last year, the two companies signed a joint research agreement (MOU) to build an AI new drug platform for the development of cationic lipids for nucleic acid delivery vehicles and established the AI model ‘AiLNPTS’. AiLNPTS was completed through repetitive AI deep learning (a technology in which a computer learns by combining and analyzing external data on its own) based on a vast amount of existing research literature and experimental data on cationic lipids for nucleic acid delivery vehicles. Through learning tests, both companies secured data reliability for discovering candidate substances and predicting efficacy of cationic lipids for AiLNPTS.
The goal of this joint research and development is to use AiLNPTS to discover cationic lipids, one of the key components of nucleic acid delivery vehicles. Cationic lipids are key substances that can bind to nucleic acids and determine the efficacy of drugs. Using the AI model, it is possible to discover cationic lipid candidates with various structures, and it is expected that efficient research, such as accurate efficacy prediction, will be possible through advanced learning of experimental results.
Under this joint research and development agreement, Azos Bio will propose new cationic lipid candidates using AI technology based on existing literature and research data, and Samyang Holdings Biopharm Group will review the candidate substances proposed by Azos Bio. , and conduct synthetic experimental research, formulation, and efficacy verification.
Cho Hye-ryeon, head of the Samyang Holdings Biopharm Group Research Center, said, “Through a long-term partnership with AzosBio, which has expertise in AI new drug development, we will continuously learn the AI platform to enhance the efficacy prediction model,” adding, “Samyang Holdings’ proprietary drug “We will continue to develop treatments that increase research efficiency and improve the quality of life of patients by combining AI technology with the delivery technology ‘SENS platform,’” he said.
Samyang Holdings Biopharm Group has focused its capabilities on drug delivery system (DDS) research for over 20 years based on bioabsorbable polymer technology and proprietary patented technology. In 2014, it established its own DDS platform ‘SENS (Stability Enhanced NanoShells)’ technology and has recently been focusing on developing innovative drug delivery systems that stably deliver biopharmaceuticals such as nucleic acids such as siRNA and mRNA into the human body.
Meanwhile, AzosBio is a company specializing in artificial intelligence platforms for new drug development. It has built a data platform (BioDL®) and an integrated artificial intelligence platform (AiDL®) and is using them for research and development. We recently expanded and relocated our headquarters and research center to the Hanam office building, establishing an in-situ R&D system that can immediately experiment and verify results predicted by artificial intelligence.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news